Leukaplasmapheresis in meningococcal septic shock.

[1]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways , 1990 .

[2]  J. Parrillo,et al.  Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. , 1989, The New England journal of medicine.

[3]  T. Hirano,et al.  Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. , 1989, Journal of immunology.

[4]  P. Brandtzaeg,et al.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome , 1989, The Journal of experimental medicine.

[5]  L. Aarden,et al.  Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.

[6]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[7]  J. Paramo,et al.  Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. , 1985, The Journal of clinical investigation.

[8]  O. Rekvig,et al.  Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. , 1984, British medical journal.

[9]  G. Krim,et al.  Prognostic factors of severe infectious purpura in children , 2004, Intensive Care Medicine.

[10]  P. Lundbergh,et al.  Prognostic Factors in meningococcal disease. , 1971, Scandinavian journal of infectious diseases.